C-RAD received the first order for a Catalyst™ and a Sentinel™ 4DCT system for a cancer treatment center in Japan, the second largest radiotherapy market worldwide. Both systems will be installed in the Katsura University Hospital located at the University of Kyoto.
In November 2014 C-RAD concluded a sales agreement with Elekta K.K. – the Japanese subsidiary of Stockholm-based Elekta AB, a global supplier of radiation treatment systems. At the same time Elekta K.K. and C-RAD obtained the required product certification for Sentinel and Catalyst in Japan. The Japanese market is the second largest radiotherapy market worldwide, with close to 800 treatment centers. C-RAD presented its certified products at the International Technical Exhibition of Medical Imaging (ITEM) conference in Japan in April 2015.
The Catalyst and the Sentinel will be delivered with the complete software configuration, containing modules for Respiratory Gating, Patient Setup and Positioning, and Motion Monitoring.
The Catalyst and Sentinel systems offer the required technology to perform high-end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.
“I am very pleased to announce this first order from Japan,” says Tim Thurn, CEO of C-RAD. “The potential of this large and progressive market will give C-RAD a significant opportunity for further growth throughout the Asian region. The first installation in a new market always enjoys very special attention, and Kyoto University is one of the highest ranked universities in Asia. We will ensure that this first customer gets rapidly up to speed with their new system. It is key to establish a Catalyst reference site for this market, allowing us to refer other customers to this installation while building up our business there. This is an excellent start with our partner in Japan.”
About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 32. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD holds 29% of the shares in laser company Cyrpa with an option to acquire the remaining 71%. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com
The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).
